Literature DB >> 20142058

[PSA and spironolactone].

S Rybikowski1, C Maurin, J Deturmeny, V Delaporte, E Lechevallier, C Coulange.   

Abstract

The spironolactone is a diuretic of potassium savings. It is also used in the treatment of the hirsutism for its antiandrogenic action. Its use and its effects on the patients affected by a prostate cancer are less known. We report the case of a 72-year-old man having a cancer of prostate which normalized its PSA after institution of a treatment by spironolactone for ascites. This patient had a biological recurrence of a prostate cancer, arisen 7 years later after a treatment by hormonal radiotherapy. Nine months after the implementation of the treatment by spironolactone, there were no clinical and biological signs of disease progress. (c) 2009. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20142058     DOI: 10.1016/j.purol.2009.04.002

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  2 in total

1.  Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate.

Authors:  Santhanam Sundar; Peter D Dickinson
Journal:  BMJ Case Rep       Date:  2012-02-25

Review 2.  The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer.

Authors:  José A Carlos-Escalante; Marcela de Jesús-Sánchez; Alejandro Rivas-Castro; Pavel S Pichardo-Rojas; Claudia Arce; Talia Wegman-Ostrosky
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.